---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-015231"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T06:01:34.327884+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q1 revenue $9.4M (-8% YoY), Advanced Energy +6%, net loss narrows to $4.2M

## Summary
- Net loss attributable to stockholders $4.2M ($0.10/sh) vs $7.6M ($0.22/sh) prior year; adjusted EBITDA loss $2.4M vs $5.3M.
- Advanced Energy revenue up 6% to $7.9M; OEM down 45% to $1.5M. Total revenue $9.4M vs $10.2M.
- Reaffirmed FY2025 guidance: total revenue $47.6M-$49.0M, Advanced Energy $39.6M-$41.0M, OEM ~$8.0M.
- Planned launch of AYON Body Contouring System in H2 2025 pending FDA clearance; 510(k) submitted Q1 2025.
- Renuvion won 2025 NewBeauty Award for 'Best Minimally Invasive Skin Tightener'; Dolores Catania named Chief of Confidence.

## SEC filing metadata
- accession: 0001437749-25-015231
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774925015231/0001437749-25-015231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774925015231/apyx20250316_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-015231
- JSON: https://secwatch.observer/filing/0001437749-25-015231.json
- Plain text: https://secwatch.observer/filing/0001437749-25-015231.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.